News Releases

News Releases

November 19, 2018
Nov
19
2018

Enlivex Therapeutics is a private, venture-funded clinical stage immunotherapy company developing an allogeneic drug pipeline for immune system rebalancing, which is critical for the treatment of life-threatening immune and inflammatory conditions that involve the hyper-expression of cytokines...

Continue reading

July 26, 2018
Jul
26
2018

<p>TEL AVIV, Israel and NEW YORK , July 26, 2018 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN) is providing an update on business development activities as well as notice of an organization change that affects members of the board and management.</p> ...

Continue reading

November 02, 2017
Nov
02
2017

TEL AVIV, Israel , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the third quarter ended September 30, 2017 . Third Quarter 2017 Financial Results and Cash Position R&amp;D...

Continue reading

September 25, 2017
Sep
25
2017

Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on September 25, 2017 TEL AVIV, Israel , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of a five to one reverse split...

Continue reading

August 04, 2017
Aug
04
2017

TEL AVIV, Israel , Aug. 04, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the second quarter ended June 30, 2017 . Second Quarter 2017 Financial Results and Cash Position R&amp;D...

Continue reading

August 04, 2017
Aug
04
2017

TEL AVIV, Israel , Aug. 04, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the second quarter ended June 30, 2017 . Second Quarter 2017 Financial Results and Cash Position R&amp;D...

Continue reading

June 05, 2017
Jun
05
2017

JSB-Partners Engaged to Lead the Effort Company Receives Regulatory Clearance to Initiate a Phase 2b trial of Trehalose in OPMD patients TEL AVIV, Israel , June 05, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today...

Continue reading

May 26, 2017
May
26
2017

TEL AVIV, Israel , May 26, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the first quarter ended March 31, 2017 . First Quarter 2017 Financial Results and Cash Position R&amp;D...

Continue reading